SC
CRL icon

Swan Capital’s Charles River Laboratories CRL Stock Holding History

Swan Capital’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.3K Buy
59
+12
+26% +$2.14K ﹤0.01% 175
2026
Q1 		$8.06K Hold
47
– – ﹤0.01% 221
2025
Q4 		$9.33K Hold
47
– – ﹤0.01% 179
2025
Q3 		$7.32K Hold
47
– – ﹤0.01% 183
2025
Q2 		$7.09K Hold
47
– – ﹤0.01% 193
2025
Q1 		$7.04K Hold
47
– – ﹤0.01% 169
2024
Q4 		$8.63K Hold
47
– – ﹤0.01% 140
2024
Q3 		$9.21K Hold
47
– – ﹤0.01% 143
2024
Q2 		$9.66K Buy
+47
New +$10.7K 0.01% 130

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Swan Capital's CRL Position: Q2 2026 in Review

Swan Capital increased its Charles River Laboratories (CRL) stake by 26% in Q2 2026, buying an estimated $2.14K and bringing the position to 59 shares worth $13.3K. The position accounts for ﹤0.01% of the portfolio, ranked #175.

Swan Capital first reported a position in CRL in Q2 2024 and has held it in 9 quarters since. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Swan Capital held 59 shares of Charles River Laboratories worth $13.3K as of Q2 2026.
  • Swan Capital bought 12 Charles River Laboratories shares in Q2 2026, an estimated $2.14K.
  • Charles River Laboratories made up ﹤0.01% of Swan Capital's portfolio in Q2 2026, its #175 holding.
  • Swan Capital first reported a position in Charles River Laboratories in Q2 2024 and has held it in 9 quarters since.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Swan Capital's 13F filing for Q2 2026, filed 13 Aug 2026.